This leads to the expansion of autoreactive B-cells that are identified in many autoimmune disorders, including Sjogren’s syndrome, systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA), making BAFF an attractive target for immunomodulatory disease therapy [20,21]. Here, TNFSF13B is linked to systemic lupus erythematosus.